Jazz Pharmaceuticals (JAZZ) on Monday reported long-term survival results from a phase 2 trial evaluating its investigational HER2-targeted therapy Ziihera in combination with chemotherapy as a first-line treatment for HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma.
The company said median overall survival reached 36.5 months among the 46 enrolled patients, with a median progression-free survival of 12.5 months. In the subgroup of 41 patients with centrally confirmed HER2-positive tumors, median progression-free survival was 15.2 months.
The data was presented at the American Society of Clinical Oncology annual meeting.
A Phase 3 trial evaluating Ziihera in the same indication is ongoing, with top-line results expected in the second half of 2025, Jazz said.
Price: 108.84, Change: +0.77, Percent Change: +0.71
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。